偶然性与偶然性对比 在阿尔茨海默氏症和帕金森病的工程纳米粒子:病理途径和治疗干预措施
Hanyu Li1,2, Ning Wang1,2, Xiaobo Mao1,2,3,4,5
1Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Nano research
|September 22, 2025
概括
纳米颗粒 (NP) 在神经退行性疾病 (如阿尔茨海默氏症和帕金森症) 中具有双重作用. 本综述探讨了偶然性和工程性NP,它们的毒理学,以及治疗这些疾病的治疗潜力.
科学领域:
- 纳米医学是一种纳米医学.
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
背景情况:
- 纳米粒子 (NP) 在神经退行中表现出双重作用,影响阿尔茨海默病 (AD) 和帕金森病 (PD).
- 来自环境来源的偶然的NP可以诱导氧化应激和神经炎症.
- 工程NP为神经退行性疾病的向诊断和治疗提供了潜在的潜力.
研究的目的:
- 审查偶然和工程纳米粒子 (NP) 在神经退行中的双重作用.
- 根据来源和成分对NP进行分类,并总结其毒理学和治疗应用.
- 确定纳米技术在神经退行性疾病治疗中的局限性和未来优先事项.
主要方法:
- 文献综述将基于来源的类别 (偶然与工程) 与基于组成的类别 (基于金属,基于碳,聚合物/无机).
- 对AD和PD的NP暴露途径,机械毒理学和工程干预措施的摘要.
- 评估当前的限制,包括生物相容性和临床相关性.
主要成果:
- 偶然的NP与氧化应激,神经炎症和AD和PD中血脑屏障的破坏有关.
- 工程NP (例如,纳米体,纳米酶) 促进有针对性的传递,神经免疫调节和干扰蛋白质聚合.
- 根据来源和组成对NP进行分类,为了解其影响和应用提供了一个框架.
结论:
- 纳米技术为诊断和治疗神经退行性疾病提供了重大机会.
- 解决生物相容性和慢性暴露相关性等局限性对于临床转化至关重要.
- 进一步的研究重点包括临床基准测试和开发用于AD和PD的实用纳米诊断和治疗方法.
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:22Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
01:37Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
01:24Parkinson's Disease: Treatment
987
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987